A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation

设为首页

收藏本站

网站地图 | English | 公务邮箱

About the library

Background
History
Leadership
Organization

Readers' Guide

Opening Hours
Collections
Help Via Email

Publications

Electronic Information Resources

A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation

详细信息查看全文

作者：Pooja Khandelwal¹ ; ² ; ^{Pooja.khandelwal@cchmc.org" class="auth_mail" title="E-mail the corresponding author} ; Chie Emoto³ ; Tsuyoshi Fukuda² ; ³ ; Alexander A. Vinks² ; ³ ; Lisa Neumeier¹ ; Christopher E. Dandoy¹ ; ² ; Javier El-Bietar¹ ; ² ; Sharat Chandra¹ ; ² ; Stella M. Davies¹ ; ² ; Jacob J. Bleesing¹ ; ² ; Michael B. Jordan¹ ; ² ; ⁴ ; Parinda A. Mehta¹ ; ² ; Sonata Jodele¹ ; ² ; Michael S. Grimley¹ ; ² ; Ashish Kumar¹ ; ² ; ⁵ ; Kasiani C. Myers¹ ; ² ; Rebecca A. Marsh¹ ; ²
关键词：Alemtuzumab ; Graft-versus-host disease (GVHD) ; Steroid-refractory acute graft-versus-host disease (SR-aGVHD) ; Alemtuzumab in children ; Alemtuzumab for GVHD
刊名：Biology of Blood and Marrow Transplantation
出版年：2016
出版时间：December 2016
年：2016
卷：22
期：12
页码：2220-2225
全文大小：935 K

文摘

•: Alemtuzumab has an overall response rate of 67% as a second-line agent for steroid-refractory acute graft-versus-host disease
•: Higher alemtuzumab levels on day 6 from first alemtuzumab dose were associated with complete response.